EUVIMEDEUVIMED entdecken
Open Access

National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States

Quinn T Ostrom iD, Madison L Shoaf, Gino Cioffi iD, Kristin Waite, Carol Kruchko, Patrick Y Wen, Daniel J Brat, Jill S Barnholtz-Sloan, J Bryan Iorgulescu

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noac198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Quinn T Ostrom und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. Hauptthemen laut MEDLINE: Glioblastoma, Glioma, Brain Neoplasms, Astrocytoma. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Centers for Disease Control and Prevention, American Brain Tumor Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecularly-defined diffuse glioma types—including IDH-wildtype glioblastoma, IDH-mutant astrocytoma, IDH-mutant 1p/19q-codeleted oligodendroglioma, and H3 K27M-mutant diffuse midline glioma—were incorporated into U.S. cancer registry reporting for individuals with brain tumors beginning in 2018. We leveraged these new data to estimate the national-level overall survival (OS) patterns associated with glioma integrated diagnoses.

Methods

Individuals diagnosed with diffuse gliomas in 2018 and had brain molecular marker data were identified within the U.S. National Cancer Database. OS was estimated using Kaplan–Meier methods and stratified by WHO CNS grade, age, sex, tumor size, treatment, extent of resection, and MGMT promoter methylation. Additionally, the effects of WHO CNS grade were examined among individuals with IDH-wildtype astrocytic gliomas.

Results

8651 individuals were identified. One-year OS was 53.7% for WHO grade 4 IDH-wildtype glioblastomas; 98.0%, 92.4%, and 76.3% for WHO grade 2, 3, and 4 IDH-mutant astrocytomas, respectively; 97.9% and 94.4% for WHO grade 2 and 3 IDH-mutant 1p/19q-codeleted oligodendrogliomas, respectively; and 55.9% for H3 K27M-mutant diffuse midline gliomas. Among IDH-wildtype glioblastomas, median OS was 17.1 months and 12.4 months for methylated and unmethylated MGMT promoters. Additionally, IDH-wildtype diffuse astrocytic gliomas reported as WHO grade 2 or 3 demonstrated longer OS compared to grade 4 tumors (both P < .001).

Conclusions

Our findings provide the initial national OS estimates for molecularly-defined diffuse gliomas in the United States and illustrate the importance of incorporating such data into cancer registry reporting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaGliomaBrain NeoplasmsAstrocytomaOligodendrogliomaHumansPrognosisMutationIsocitrate Dehydrogenase

Stichwörter der Autor:innen

IDH mutationMGMT promoter methylationdiffuse gliomaglioblastomasurvival

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.
  • Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.
  • The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, NC, USA.
  • Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Division of Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

ORCID-Profile: Quinn T Ostrom, Gino Cioffi

Förderung

  • NCI NIH HHS
  • Centers for Disease Control and Prevention
  • American Brain Tumor Association
  • Novocure
  • the Musella Foundation
  • National Brain Tumor Society
  • Pediatric Brain Tumor Foundation
  • The Sontag Foundation

Zitieren

APA

Ostrom, Q. T., Shoaf, M. L., Cioffi, G., Waite, K., Kruchko, C., Wen, P. Y., Brat, D. J., Barnholtz-Sloan, J. S., & Iorgulescu, J. B. (2023). National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac198

Vancouver

Ostrom QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY, et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac198

BibTeX
@article{Ostrom2023,
  author = {Ostrom, Quinn T and Shoaf, Madison L and Cioffi, Gino and Waite, Kristin and Kruchko, Carol and Wen, Patrick Y and Brat, Daniel J and Barnholtz-Sloan, Jill S and Iorgulescu, J Bryan},
  title = {National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noac198}
}
Kostenlos starten →